Addex Therapeutics (FRA:APE1) Moat Score: 3/10 (As of Jul. 08, 2026)


FRA:APE1 Addex Therapeutics Ltd FRA:APE1
7 GF Score
Price €5.05
GF Value €1.16
! 6 Warning Signs
View Full Analysis

What is Addex Therapeutics Moat Score?

Addex Therapeutics FRA:APE1 +5.21% 7 Moat Score is 3 as of Jul. 08, 2026. GuruFocus rates FRA:APE1 with a GF Score™ of 7/100 and a GF Value™ of €1.16. The stock has 6 warning signs investors should review. Among 1,393 Biotechnology companies, Addex Therapeutics ranks better than 75.52% on this metric.

Addex Therapeutics has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Addex Therapeutics has No Moat: Addex Therapeutics has a weak moat due to its early-stage drug development pipeline and limited market presence. It lacks significant intellectual property or regulatory approvals to establish a sustainable competitive advantage.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Addex Therapeutics might have No Moat - Very weak/transient advantages.

Addex Therapeutics  (FRA:APE1) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Addex Therapeutics Moat Score Related Terms

FRA:APE1 vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, Addex Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Addex Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Addex Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Addex Therapeutics's Moat Score falls into.


FRA:APE1
7GF Score
Addex Therapeutics Ltd FRA:APE1
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Addex Therapeutics (FRA:APE1) has a Moat Score of 3 as of Jul. 08, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Addex Therapeutics ranks #341 out of 1393 companies in the Biotechnology industry, placing it in the top 24.5%.
Is Addex Therapeutics' Moat Score too high?
Addex Therapeutics' current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Addex Therapeutics' value of 3 is 50% above this industry median. Based on the distribution chart, Addex Therapeutics ranks #341 out of 1393 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Addex Therapeutics has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Addex Therapeutics' Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Addex Therapeutics ranks #341 out of 1393 companies for Moat Score. This places Addex Therapeutics in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Addex Therapeutics' value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,393 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Addex Therapeutics's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Addex Therapeutics's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Addex Therapeutics stock overvalued right now?
Addex Therapeutics (FRA:APE1) has a current Moat Score of 3. The stock's GF Value™ is €1.16, compared to a current price of €5.05 — trading 335.3% above its estimated fair value. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Addex Therapeutics' overall GF Score™ is 7/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Addex Therapeutics (FRA:APE1), the current Moat Score is 3 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Addex Therapeutics (FRA:APE1) Overvalued in 2026?

Based on GuruFocus' analysis, Addex Therapeutics stock appears to be overvalued. The current stock price of €5.05 is trading 335.3% above its estimated GF Value™ of €1.16.

Key valuation signals for FRA:APE1:

  • Moat Score: 3
  • GF Value™: €1.16 vs. price of €5.05 (335.3% above fair value)
  • GF Score™: 7/100 with 6 warning signs
  • Industry Position: 50% above the Biotechnology median (#341 of 1393)

No single metric tells the full story. See the FRA:APE1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Addex Therapeutics Business Description

Address Chemin des Mines 9, Geneva, CHE, 1202
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
7GF Score

Get the complete analysis for FRA:APE1

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.05
Price
€1.16
GF Value